A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults who have Left Ventricular Systolic Dysfunction following Myocardial Infarction.
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs NP 202 (Primary)
- Indications Left ventricular dysfunction; Myocardial infarction
- Focus Therapeutic Use
- Sponsors Armaron Biosciences
- 26 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Feb 2018.
- 26 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated